OPHIDION, INC. — Department of Health and Human Services SBIR Phase II: R44

OPHIDION, INC. — SBIR Phase II award from Department of Health and Human Services.

Amount
$793,191
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase II
Topic
R44
Solicitation
PA14-071
NAICS
Place of performance
CA
Period
2015-05-01 → 2018-04-30

Description

DESCRIPTION provided by applicant Nicotine is a serious health problem that is resistant to treatment for millions of people In the United States tobacco use is responsible for about deaths per year and an estimated of these tobacco related deaths are the result of secondhand smoke exposure Cigarette smoking costs more than $ billion i e $ billion in lost productivity plus $ billion in health care expenditures Nicotine is one of the most heavily used addictive drugs and accounts for of lung cancer cases in the U S Nicotine the addictive component of tobacco binds to specialized proteins in the brain called a nicotinic receptors Evidence suggests that a receptors can be a contributing factor in the risk towards smoking dependence indicating its potential as a therapeutic development strategy for smoking cessation Common strategies for smoking cessation therapies are to break the reward cycle between smoking and the reward pleasure signal that is the typical consequence of nicotine consumption a receptors are located in a brain region that mediates aversion to nicotine the medial habenula Activation of the medial habenula can cause reduction of nicotine intake in animal models This proposal focuses on the development of a drug that activates a receptors to help smokers quit smoking The research performed under this award will transform early stage candidate molecules into drug like pre clinical leads A successful project outcome will be the development of a clinical candidate that can be tested in humans with the end goal of delivering a smoking cessation drug to the public PUBLIC HEALTH RELEVANCE This proposal focuses on the development of a drug to help addicted smokers quit smoking Tobacco use is responsible for about deaths per year in the US and an estimated of these tobacco related deaths are the result of secondhand smoke exposure Nicotine related diseases place a heavy burden on the health care industry and have a substantial health and societal impact